{"id":"cetrorelix","rwe":[{"pmid":"41864162","year":"2026","title":"A new cetrorelix-based estrogen-free ovarian synchronization protocol for fixed-time artificial insemination in beef cattle.","finding":"","journal":"Theriogenology","studyType":"Clinical Study"},{"pmid":"41722737","year":"2026","title":"Hydrogel and oleogel formulation of the decapeptide cetrorelix acetate for nasal administration.","finding":"","journal":"European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences","studyType":"Clinical Study"},{"pmid":"41668890","year":"2025","title":"Targeting angiogenesis in endometriosis: a systematic review and network meta-analysis of VEGF-directed pharmacotherapies.","finding":"","journal":"Frontiers in reproductive health","studyType":"Clinical Study"},{"pmid":"41534335","year":"2026","title":"Crosstalk with the cholinergic pathway may be responsible for chlorpyrifos-induced reproductive toxicity in fish.","finding":"","journal":"Aquatic toxicology (Amsterdam, Netherlands)","studyType":"Clinical Study"},{"pmid":"41478293","year":"2026","title":"Oocyte cryo-preservation for fertility preservation: a comparative study of efficacy and cost-effectiveness between progestin-primed and antagonist ovarian stimulation protocol.","finding":"","journal":"Human fertility (Cambridge, England)","studyType":"Clinical Study"}],"_fda":{"id":"ab90e510-eecd-4d5f-b2df-059d3cbfc8f0","set_id":"89f8f8ee-68ac-4ed0-a7e3-ffd6e0c1290a","openfda":{"rxcui":["283402"],"spl_id":["ab90e510-eecd-4d5f-b2df-059d3cbfc8f0"],"brand_name":["cetrorelix acetate"],"spl_set_id":["89f8f8ee-68ac-4ed0-a7e3-ffd6e0c1290a"],"package_ndc":["68083-600-01","68083-598-01","68083-599-01"],"product_ndc":["68083-600"],"generic_name":["CETRORELIX ACETATE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"manufacturer_name":["Gland Pharma Limited"],"application_number":["ANDA218150"],"is_original_packager":[true]},"version":"6","warnings":["WARNINGS Cetrorelix acetate for injection should be prescribed by physicians who are experienced in fertility treatment. Before starting treatment with cetrorelix acetate for injection, pregnancy must be excluded (see CONTRAINDICATIONS and PRECAUTIONS)."],"overdosage":["OVERDOSAGE There have been no reports of overdosage with cetrorelix acetate for injection 0.25 mg or 3 mg in humans. Single doses up to 120 mg cetrorelix acetate for injection have been well tolerated in patients treated for other indications without signs of overdosage."],"description":["DESCRIPTION Cetrorelix acetate for injection is a synthetic decapeptide with gonadotropin-releasing hormone (GnRH) antagonistic activity. Cetrorelix acetate is an analog of native GnRH with substitutions of amino acids at positions 1, 2, 3, 6, and 10. The molecular formula is Acetyl-D-3-(2´-naphtyl)-alanine-D-4-chlorophenylalanine-D-3-(3´-pyridyl)-alanine -L-serine-L-tyrosine-D-citruline-L-leucine-L-arginine-L-proline-D-alanine-amide, and the molecular weight is 1431.06, calculated as the anhydrous free base. The structural formula is as follows: Cetrorelix acetate (Ac-D-Nal 1 - D -Cpa 2 - D -Pal 3 -Ser 4 -Tyr 5 - D -Cit 6 -Leu 7 -Arg 8 -Pro 9 - D -Ala 10 -NH 2 ) Cetrorelix Acetate for Injection 0.25 mg is a sterile lyophilized powder intended for subcutaneous injection after reconstitution with Sterile Water for Injection, USP, that comes supplied in a 1.0 mL pre-filled syringe. Each vial of cetrorelix acetate for injection 0.25 mg contains 0.26-0.27 mg cetrorelix acetate, equivalent to 0.25 mg cetrorelix, and 54.8 mg mannitol. cetro-spl-structure"],"precautions":["PRECAUTIONS General Cases of hypersensitivity reactions, including anaphylactoid reactions with the first dose, have been reported during post-marketing surveillance (see ADVERSE REACTIONS). A severe anaphylactic reaction associated with cough, rash, and hypotension, was observed in one patient after seven months of treatment with cetrorelix acetate for injection (10 mg/day) in a study for an indication unrelated to infertility. Special care should be taken in women with signs and symptoms of active allergic conditions or known history of allergic predisposition. Treatment with cetrorelix acetate for injection is not advised in women with severe allergic conditions. Information for Patients Prior to therapy with cetrorelix acetate for injection, patients should be informed of the duration of treatment and monitoring procedures that will be required. The risk of possible adverse reactions should be discussed (see ADVERSE REACTIONS). Cetrorelix acetate for injection should not be prescribed if a patient is pregnant. If cetrorelix acetate for injection is prescribed to patients for self-administration, information for proper use is given in the Patient Leaflet (see below). Laboratory Tests After the exclusion of preexisting conditions, enzyme elevations (ALT, AST, GGT, alkaline phosphatase) were found in 1-2% of patients receiving cetrorelix acetate for injection during controlled ovarian stimulation. The elevations ranged up to three times the upper limit of normal. The clinical significance of these findings was not determined. During stimulation with human menopausal gonadotropin, cetrorelix acetate for injection had no notable effects on hormone levels aside from inhibition of LH surges. Drug Interactions No formal drug interaction studies have been performed with cetrorelix acetate for injection. Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term carcinogenicity studies in animals have not been performed with cetrorelix acetate. Cetrorelix acetate was not genotoxic in vitro (Ames test, HPRT test, chromosome aberration test) or in vivo (chromosome aberration test, mouse micronucleus test). Cetrorelix acetate induced polyploidy in CHL-Chinese hamster lung fibroblasts, but not in V79-Chinese hamster lung fibroblasts, cultured peripheral human lymphocytes or in an in vitro micronucleus test in the CHL-cell line. Treatment with 0.46 mg/kg cetrorelix acetate for 4 weeks resulted in complete infertility in female rats which was reversed 8 weeks after cessation of treatment. Pregnancy (see CONTRAINDICATIONS ) Cetrorelix acetate for injection is contraindicated in pregnant women. When administered to rats for the first seven days of pregnancy, cetrorelix acetate did not affect the development of the implanted conceptus at doses up to 38 mcg/kg (approximately 1 times the recommended human therapeutic dose based on body surface area). However, a dose of 139 mcg/kg (approximately 4 times the human dose) resulted in a resorption rate and a postimplantation loss of 100%. When administered from day 6 to near term to pregnant rats and rabbits, very early resorptions and total implantation losses were seen in rats at doses from 4.6 mcg/kg (0.2 times the human dose) and in rabbits at doses from 6.8 mcg/kg (0.4 times the human dose). In animals that maintained their pregnancy, there was no increase in the incidence of fetal abnormalities. The fetal resorption observed in animals is a logical consequence of the alteration in hormonal levels effected by the antigonadotrophic properties of cetrorelix acetate for injection, which could result in fetal loss in humans as well. Therefore, this drug should not be used in pregnant women. Nursing Mothers It is not known whether cetrorelix acetate for injection is excreted in human milk. Because many drugs are excreted in human milk, and because the effects of cetrorelix acetate for injection on lactation and/or the breast-fed child have not been determined, cetrorelix acetate for injection should not be used by nursing mothers. Geriatric Use Cetrorelix acetate for injection is not intended to be used in subjects aged 65 and over."],"how_supplied":["HOW SUPPLIED Cetrorelix Acetate for Injection 0.25 mg is available in a carton of one packaged tray (NDC 68083-600-01). Each packaged tray contains: one glass vial containing 0.26 - 0.27 mg cetrorelix acetate (corresponding to 0.25 mg cetrorelix), one pre-filled glass syringe with 1 mL of Sterile Water for Injection, USP, one 20 gauge needle (yellow) and one 27 gauge needle (grey). Storage Store Cetrorelix Acetate for Injection 0.25 mg refrigerated, 2-8°C (36-46°F). Store the packaged tray in the outer carton in order to protect from light. Rx only Manufactured by: Gland Pharma Limited, Unit-II, Plot No. 42-52, Sy. No. 166, 171, 172 & 177, Phase-III, TSIIC, Pashamylaram Village, Patancheru Mandal, Sangareddy District - 502 307, Telangana State, India. Revised: February 2024"],"effective_time":"20240808","adverse_reactions":["ADVERSE REACTIONS The safety of cetrorelix acetate for injection in 949 patients undergoing controlled ovarian stimulation in clinical studies was evaluated. Women were between 19 and 40 years of age (mean: 32). 94.0% of them were Caucasian. Cetrorelix acetate for injection was given in doses ranging from 0.1 mg to 5 mg as either a single or multiple dose. Table 3 shows systemic adverse events, reported in clinical studies without regard to causality, from the beginning of cetrorelix acetate for injection treatment until confirmation of pregnancy by ultrasound at an incidence ≥ 1% in cetrorelix acetate for injection treated subjects undergoing COS. Table 3: Adverse Events in ≥1% (WHO preferred term) Cetrorelix Acetate for Injection N=949 % (n) Ovarian Hyperstimulation Syndrome* 3.5 (33) Nausea 1.3 (12) Headache 1.1 (10) * Intensity moderate or severe, or WHO Grade II or III, respectively Local site reactions (e.g. redness, erythema, bruising, itching, swelling, and pruritus) were reported. Usually, they were of a transient nature, mild intensity and short duration. During post-marketing surveillance, cases of mild to moderate Ovarian Hyperstimulation syndrome and cases of hypersensitivity reactions including anaphylactoid reactions have been reported. Two stillbirths were reported in Phase 3 studies of cetrorelix acetate for injection. Congenital Anomalies Clinical follow-up studies of 316 newborns of women administered cetrorelix acetate for injection were reviewed. One infant of a set of twin neonates was found to have anencephaly at birth and died after four days. The other twin was normal. Developmental findings from ongoing baby follow-up included a child with a ventricular septal defect and another child with bilateral congenital glaucoma. Four pregnancies that resulted in therapeutic abortion in Phase 2 and Phase 3 controlled ovarian stimulation studies had major anomalies (diaphragmatic hernia, trisomy 21, Klinefelter syndrome, polymalformation, and trisomy 18). In three of these four cases, intracytoplasmic sperm injection (ICSI) was the fertilization method employed; in the fourth case, in vitro fertilization (IVF) was the method employed. The minor congenital anomalies reported include: supernumerary nipple, bilateral strabismus, imperforate hymen, congenital nevi, hemangiomata, and QT syndrome. The causal relationship between the reported anomalies and cetrorelix acetate for injection is unknown. Multiple factors, genetic and others (including, but not limited to ICSI, IVF, gonadotropins, and progesterone) make causal attribution difficult to study. To report SUSPECTED ADVERSE REACTIONS contact Gland Pharma Limited at (609)-250‐7990 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch."],"contraindications":["CONTRAINDICATIONS Cetrorelix acetate for injection is contraindicated under the following conditions: 1. Hypersensitivity to cetrorelix acetate, extrinsic peptide hormones or mannitol. 2. Known hypersensitivity to GnRH or any other GnRH analogs. 3. Known or suspected pregnancy, and lactation (see PRECAUTIONS). 4. Severe renal impairment."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY GnRH induces the production and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH) from the gonadotrophic cells of the anterior pituitary. Due to a positive estradiol (E2) feedback at midcycle, GnRH liberation is enhanced resulting in an LH-surge. This LH-surge induces the ovulation of the dominant follicle, resumption of oocyte meiosis and subsequently luteinization as indicated by rising progesterone levels. Cetrorelix acetate for injection competes with natural GnRH for binding to membrane receptors on pituitary cells and thus controls the release of LH and FSH in a dose-dependent manner. The onset of LH suppression is approximately one hour with the 3 mg dose and two hours with the 0.25 mg dose. This suppression is maintained by continuous treatment and there is a more pronounced effect on LH than on FSH. An initial release of endogenous gonadotropins has not been detected with cetrorelix acetate for injection, which is consistent with an antagonist effect. The effects of cetrorelix acetate for injection on LH and FSH are reversible after discontinuation of treatment. In women, cetrorelix acetate for injection delays the LH-surge, and consequently ovulation, in a dose-dependent fashion. FSH levels are not affected at the doses used during controlled ovarian stimulation. Following a single 3 mg dose of cetrorelix acetate for injection, duration of action of at least 4 days has been established. A dose of cetrorelix acetate for injection 0.25 mg every 24 hours has been shown to maintain the effect. Pharmacokinetics The pharmacokinetic parameters of single and multiple doses of cetrorelix acetate for injection in adult healthy female subjects are summarized in Table 1. Table 1: Pharmacokinetic parameters of Cetrorelix Acetate for Injection following 3 mg single or 0.25 mg single and multiple (daily for 14 days) subcutaneous (sc) administration. Single dose 3 mg Single dose 0.25 mg Multiple dose 0.25 mg No. of subjects 12 12 12 t max *[h] 1.5 (0.5-2) 1.0 (0.5-1.5) 1.0 (0.5-2) t 1/2 *[h] 62.8 (38.2-108) 5.0 (2.4-48.8) 20.6 (4.1-179.3) C max [ng/ml] 28.5 (22.5-36.2) 4.97 (4.17-5.92) 6.42 (5.18-7.96) AUC [ng∙h/ml] 536 (451-636) 31.4 (23.4-42.0) 44.5 (36.7-54.2) CL † [ml/min∙kg] 1.28 ‡ Vz † [l/kg] 1.16 ‡ t max Time to reach observed maximum plasma concentration t 1/2 Elimination half-life C max Maximum plasma concentration; multiple dose C ss, max AUC Area under the curve; single dose AUC 0-inf , multiple dose AUC t CL Total plasma clearance Vz Volume of distribution Geometric mean (95% Cl In ), * median (min-max) † arithmetic mean, ‡ Based on iv administration (n=6, separate study 0013) Absorption Cetrorelix acetate for injection is rapidly absorbed following subcutaneous injection, maximal plasma concentrations being achieved approximately one to two hours after administration. The mean absolute bioavailability of cetrorelix acetate for injection following subcutaneous administration to healthy female subjects is 85%. Distribution The volume of distribution of cetrorelix acetate for injection following a single intravenous dose of 3 mg is about 1 l/kg. In vitro protein binding to human plasma is 86%. Cetrorelix acetate for injection concentrations in follicular fluid and plasma were similar on the day of oocyte pick-up in patients undergoing controlled ovarian stimulation. Following subcutaneous administration of cetrorelix acetate for injection 0.25 mg and 3 mg, plasma concentrations of cetrorelix were below or in the range of the lower limit of quantitation on the day of oocyte pick-up and embryo transfer. Metabolism After subcutaneous administration of 10 mg cetrorelix acetate for injection to females and males, cetrorelix acetate for injection and small amounts of (1-9), (1-7), (1-6), and (1-4) peptides were found in bile samples over 24 hours. In in vitro studies, cetrorelix acetate for injection was stable against phase I- and phase II-metabolism. Cetrorelix acetate for injection was transformed by peptidases, and the (1-4) peptide was the predominant metabolite. Excretion Following subcutaneous administration of 10 mg cetrorelix to males and females, only unchanged cetrorelix was detected in urine. In 24 hours, cetrorelix and small amounts of the (1-9), (1-7), (1-6), and (1-4) peptides were found in bile samples. 2-4% of the dose was eliminated in the urine as unchanged cetrorelix, while 5-10% was eliminated as cetrorelix and the four metabolites in bile. Therefore, only 7-14% of the total dose was recovered as unchanged cetrorelix and metabolites in urine and bile up to 24 hours. The remaining portion of the dose may not have been recovered since bile and urine were not collected for a longer period of time. Special Populations Pharmacokinetic investigations have not been performed either in subjects with impaired renal or liver function, or in the elderly, or in children (see PRECAUTIONS). Pharmacokinetic differences in different races have not been determined. There is no evidence of differences in pharmacokinetic parameters for cetrorelix acetate for injection between healthy subjects and patients undergoing controlled ovarian stimulation. Drug-Drug Interactions No formal drug-drug interaction studies have been performed with cetrorelix acetate for injection (see PRECAUTIONS). Clinical Studies Seven hundred thirty two (732) patients were treated with cetrorelix acetate for injection in five (two Phase 2 dose-finding and three Phase 3) clinical trials. The clinical trial population consisted of Caucasians (95.5%) and Black, Asian, Arabian and others (4.5%). Women were between 19 and 40 years of age (mean: 32). The studies excluded subjects with polycystic ovary syndrome (PCOS), subjects with low or no ovarian reserve, and subjects with stage III-IV endometriosis. Two dose regimens were investigated in these clinical trials, either a single dose per treatment cycle or multiple dosing. In the Phase 2 studies, a single dose of 3 mg was established as the minimal effective dose for the inhibition of premature LH surges with a protection period of at least 4 days. When cetrorelix acetate for injection is administered in a multidose regimen, 0.25 mg was established as the minimal effective dose. The extent and duration of LH-suppression is dose dependent. In the Phase 3 program, efficacy of the single 3 mg dose regimen of cetrorelix acetate for injection and the multiple 0.25 mg dose regimen of cetrorelix acetate for injection was established separately in two adequate and well controlled clinical studies utilizing active comparators. A third non-comparative clinical study evaluated only the multiple 0.25 mg dose regimen of cetrorelix acetate for injection. The ovarian stimulation treatment with recombinant FSH or human menopausal gonadotropin (hMG) was initiated on day 2 or 3 of a normal menstrual cycle. The dose of gonadotropins was administered according to the individual patient's disposition and response. In the single dose regimen study, cetrorelix acetate for injection 3 mg was administered on the day of controlled ovarian stimulation when adequate estradiol levels (400 pg/mL) were obtained, usually on day 7 (range day 5-12). If hCG was not given within 4 days of the 3 mg dose of cetrorelix acetate for injection, then 0.25 mg of cetrorelix acetate for injection was administered daily beginning 96 hours after the 3 mg injection until and including the day of hCG administration. In the two multiple dose regimen studies, cetrorelix acetate for injection 0.25 mg was started on day 5 or 6 of COS. Both gonadotropins and cetrorelix acetate for injection were continued daily (multiple dose regimen) until the injection of human chorionic gonadotropin (hCG). Oocyte pick-up (OPU) followed by in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) as well as embryo transfer (ET) were subsequently performed. The results for cetrorelix acetate for injection are summarized below in Table 2. Table 2: Results of Phase 3 Clinical Studies with Cetrorelix Acetate for Injection 3 mg in a single dose (sd) regimen and 0.25 mg in a multiple dose (md) regimen Parameter Cetrorelix Acetate for Injection 3 mg (sd, active comparator study) Cetrorelix Acetate for Injection 0.25 mg (md, active comparator study) Cetrorelix Acetate for Injection 0.25 mg (md, non-comparative study) No. of subjects 115 159 303 hCG administered [%] 98.3 96.2 96.0 Oocyte pick-up [%] 98.3 94.3 93.1 LH-surge [%] (LH ≥ 10 U/L and P* ≥ 1 ng/mL) † 0.0 1.9 1.0 Serum E 2 [pg/ml] at day hCG ‡,§ 1125 (470-2952) 1064 (341-2531) 1185 (311-3676) Serum LH [U/L] at day hCG ‡,§ 1.0 (0.5-2.5) 1.5 (0.5-7.6) 1.1 (0.5-3.5) No. of follicles ≥ 11 mm at day hCG ¶ 11.2±5.5 10.8±5.2 10.4±4.5 No. of oocytes: IVF ¶ ICSI ¶ 9.2±5.2 10.0±4.2 7.6±4.3 10.1±5.6 8.5±5.1 9.3±5.9 Fertilization rate: IVF ¶ ICSI ¶ 0.48±0.33 0.66±0.29 0.62±0.26 0.63±0.29 0.60±0.26 0.61±0.25 No. of embryos transferred ¶ 2.6±0.9 2.1±0.6 2.7±1.0 Clinical pregnancy rate [%] per attempt per subject with ET 22.6 26.3 20.8 24.1 19.8 23.3 * Progesterone † Following initiation of cetrorelix acetate for injection therapy ‡ Morning values § Median with 5th – 95th percentiles ¶ Mean ± standard deviation In addition to IVF and ICSI, one pregnancy was obtained after intrauterine insemination. In the five Phase 2 and Phase 3 clinical trials, 184 pregnancies have been reported out of a total of 732 patients (including 21 pregnancies following the replacement of frozen-thawed embryos). In the 3 mg regimen, 9 patients received an additional dose of 0.25 mg of cetrorelix acetate for injection and two other patients received two additional doses of 0.25 mg cetrorelix acetate for injection. The median number of days of cetrorelix acetate for injection multiple dose treatment was 5 (range 1-15) in both studies. No drug related allergic reactions were reported from these clinical studies."],"indications_and_usage":["INDICATIONS AND USAGE Cetrorelix acetate for injection is indicated for the inhibition of premature LH surges in women undergoing controlled ovarian stimulation."],"adverse_reactions_table":["<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"100%\"><colgroup/><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"center\" valign=\"middle\"><content styleCode=\"bold\">(WHO preferred term)</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\"><content styleCode=\"bold\">Cetrorelix Acetate for Injection  N=949  % (n)</content> </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\">Ovarian Hyperstimulation Syndrome* </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">3.5 (33) </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" align=\"left\" valign=\"middle\">Nausea </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">1.3 (12) </td></tr><tr><td styleCode=\"Lrule Rrule\" align=\"left\" valign=\"middle\">Headache </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">1.1 (10) </td></tr></tbody></table>"],"dosage_and_administration":["DOSAGE AND ADMINISTRATION Ovarian stimulation therapy with gonadotropins (FSH, hMG) is started on cycle Day 2 or 3. The dose of gonadotropins should be adjusted according to individual response. Cetrorelix acetate for injection 0.25 mg may be administered subcutaneously once daily during the early- to mid-follicular phase. Cetrorelix acetate for Injection 0.25 mg is administered on either stimulation day 5 (morning or evening) or day 6 (morning) and continued daily until the day of hCG administration. When assessment by ultrasound shows a sufficient number of follicles of adequate size, hCG is administered to induce ovulation and final maturation of the oocytes. No hCG should be administered if the ovaries show an excessive response to the treatment with gonadotropins to reduce the chance of developing ovarian hyperstimulation syndrome (OHSS). Administration Cetrorelix acetate for Injection 0.25 mg can be administered by the patient herself after appropriate instructions by her doctor. Directions for using Cetrorelix Acetate for Injection 0.25 mg with the enclosed needles and pre-filled syringe: 1. Wash hands thoroughly with soap and water. 2. Flip off the plastic cover of the vial and wipe the aluminum ring and the rubber stopper with an alcohol swab. 3. Twist the injection needle with the yellow mark (20 gauge) on the pre-filled syringe. 4. Push the needle through the center of the rubber stopper of the vial and slowly inject the solvent into the vial. 5. Leaving the syringe in the vial, gently swirl the vial until the solution is clear and without residues. Avoid forming bubbles. 6. Draw the total contents of the vial into the syringe. If necessary, invert the vial and pull back the needle as far as needed to withdraw the entire contents of the vial. Discard unused portion. 7. Replace the needle with the yellow mark by the injection needle with the grey mark (27 gauge). 8. Invert the syringe and push the plunger until all air bubbles have been expelled. 9. Choose an injection site in the lower abdominal area, preferably around, but staying at least one inch away from the navel. Choose a different injection site each day to minimize local irritation. Use a second alcohol swab to clean the skin at the injection site and allow alcohol to dry. Gently pinch up the skin surrounding the site of injection. 10. Inject the prescribed dose as directed by your doctor, nurse or pharmacist. 11. Use the syringe and needles only once. Dispose of the syringe and needles properly after use. If available, use a medical waste container for disposal."],"spl_product_data_elements":["cetrorelix acetate cetrorelix acetate cetrorelix acetate cetrorelix acetate CETRORELIX ACETATE CETRORELIX MANNITOL sterile water sterile water WATER"],"spl_patient_package_insert":["Patient Leaflet Cetrorelix Acetate for Injection 0.25 mg Active ingredient: cetrorelix acetate Summary Cetrorelix Acetate for Injection blocks the effects of a natural hormone, called gonadotropin-releasing hormone (GnRH). GnRH controls the secretion of another hormone, called luteinizing hormone (LH), which induces ovulation during the menstrual cycle. During hormone treatment for ovarian stimulation, premature ovulation may lead to eggs that are not suitable for fertilization. Cetrorelix Acetate for Injection blocks such undesirable premature ovulation. Uses Cetrorelix Acetate for Injection is used to prevent premature ovulation during controlled ovarian stimulation. General Cautions Do not use Cetrorelix Acetate for Injection if you • have kidney disease • are allergic to cetrorelix acetate, mannitol or exogenous peptide hormones (medicines similar to cetrorelix acetate for injection) or • are pregnant, or think that you might be pregnant, or if you are breast-feeding. Consult your doctor before taking Cetrorelix Acetate for Injection if you have had severe allergic reactions. Proper Use Ovarian stimulation therapy is started on cycle Day 2 or 3. Cetrorelix Acetate for Injection 0.25 mg is injected under the skin once daily, as directed by your physician. When an ultrasound examination shows that you are ready, another drug (hCG) is injected to induce ovulation. How should you use Cetrorelix Acetate for Injection? You may self-inject cetrorelix acetate for injection after special instruction from your doctor. To fully benefit from cetrorelix acetate for injection, please read carefully and follow the instructions given below, unless your doctor advises you otherwise. Cetrorelix acetate for injection is for injection under the skin of the lower abdominal area, preferably around, but staying at least one inch away from the belly button. Choose a different injection site each day to minimize local irritation. Dissolve cetrorelix acetate for injection powder only with the water contained in the pre-filled syringe. Do not use a cetrorelix acetate for injection, solution if it contains particles or if it is not clear. Before you inject cetrorelix acetate for injection yourself, please read the following instructions carefully: Directions for using Cetrorelix Acetate for Injection 0.25 mg with the enclosed needles and pre-filled syringe: 1. Wash your hands thoroughly with soap and water. 2. On a clean flat surface, lay out everything you need (one vial of powder, one pre-filled syringe, one injection needle with a yellow mark, and one injection needle with a grey mark). 3. Flip off the plastic cover of the vial. Wipe the aluminum ring and the rubber stopper with an alcohol swab. 4. Take the injection needle with the yellow mark and remove the wrapping. Take the pre-filled syringe and remove the cover. Twist the needle on the syringe and remove the cover of the needle. 5. Push the needle through the center of the rubber stopper of the vial. Inject the water into the vial by slowly pushing down on the plunger of the syringe. 6. Leave the syringe in the vial. While carefully holding the syringe and vial, swirl gently to mix the powder and water together. When it is mixed, it will look clear and have no particles in it. Do not shake or you will create bubbles in your medicine. 7. Draw the total contents of the vial into the syringe. If liquid is left in the vial, invert the vial, pull back the needle until the opening of the needle is just inside the stopper. If you look from the side through the gap in the stopper, you can control the movement of the needle and the liquid. It is important to withdraw the entire contents of the vial. Discard unused portion. 8. Detach the syringe from the needle and lay down the syringe. Take the injection needle with the grey mark and remove its wrapping. Twist the needle on the syringe and remove the cover of the needle. 9. Invert the syringe and push the plunger until all air bubbles have been pushed out. Do not touch the needle or allow the needle to touch any surface. 10. Choose an injection site in the lower abdominal area, preferably around, but at least one inch away from the belly button. Choose a different injection site each day to minimize local irritation. Take a second alcohol swab and clean the skin at the injection site and allow alcohol to dry. Inject the prescribed dose as directed by your doctor, nurse or pharmacist. 11. Use the syringe and needles only once. Dispose of the syringe and needles immediately after use (put the covers on the needles to avoid injury). A medical waste container should be used for disposal. SPECIAL ADVICE What do you do if you have used too much Cetrorelix Acetate for Injection? Contact your doctor in case of overdosage immediately to check whether an adjustment of the further ovarian stimulation procedure is required. Possible Side Effects Mild and short lasting reactions may occur at the injection site like reddening, itching, and swelling. Nausea and headache have also been reported. Call your doctor if you have any side effect not mentioned in this leaflet or if you are unsure about the effect of this medicine. Storage How is Cetrorelix Acetate for Injection to be stored? Store Cetrorelix Acetate for Injection in a cool dry place protected from excess moisture and heat. Store Cetrorelix Acetate for Injection 0.25 mg in the refrigerator at 2-8°C (36-46°F). Keep the packaged tray in the outer carton in order to protect it from light. How long may Cetrorelix Acetate for Injection be stored? Do not use the Cetrorelix Acetate for Injection powder or the pre-filled syringe after the expiration date, which is printed on the labels and on the carton, and dispose of the vial and the syringe properly. How long can you keep Cetrorelix Acetate for Injection after preparation of the solution? The solution should be used immediately after preparation. Store the medicine out of the reach of children. If you suspect that you may have taken more than the prescribed dose of this medicine, contact your doctor immediately. This medicine was prescribed for your particular condition. Do not use it for another condition or give the drug to others. This leaflet provides a summary of the information about Cetrorelix Acetate for Injection. Medicines are sometimes prescribed for uses other than those listed in the Leaflet. If you have any questions or concerns, or want more information about Cetrorelix Acetate for Injection, contact your doctor or pharmacist. This Leaflet has been approved by the U.S. Food and Drug Administration. Manufactured by: Gland Pharma Limited, Unit-II, Plot No. 42-52, Sy. No. 166, 171, 172 & 177, Phase-III, TSIIC, Pashamylaram Village, Patancheru Mandal, Sangareddy District - 502 307, Telangana State, India. Revised: February 2024 cetro-spl-fig-1 cetro-spl-fig-2 cetro-spl-fig-3 cetro-spl-fig-4 cetro-spl-fig-5 cetro-spl-fig-6 cetro-spl-fig-7 cetro-spl-fig-8 cetro-spl-fig-9 cetro-spl-fig-10 cetro-spl-fig-11"],"clinical_pharmacology_table":["<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"0\"><colgroup/><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\">  </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\"><content styleCode=\"bold\">Single dose 3 mg</content> </td><td styleCode=\"Rrule\" valign=\"middle\"><content styleCode=\"bold\">Single dose 0.25 mg</content> </td><td styleCode=\"Rrule\" valign=\"middle\"><content styleCode=\"bold\">Multiple dose 0.25 mg</content> </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\">No. of subjects </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">12 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">12 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">12 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\">t<sub>max</sub>*[h]   </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">1.5  (0.5-2) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">1.0  (0.5-1.5) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">1.0  (0.5-2) </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\">t<sub>1/2</sub>*[h]   </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">62.8  (38.2-108) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">5.0  (2.4-48.8) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">20.6  (4.1-179.3) </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\">C<sub>max</sub> [ng/ml] </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">28.5  (22.5-36.2) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">4.97  (4.17-5.92) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">6.42  (5.18-7.96) </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\">AUC [ng&#x2219;h/ml] </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">536  (451-636) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">31.4  (23.4-42.0) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">44.5  (36.7-54.2) </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\">CL<sup>&#x2020;</sup>[ml/min&#x2219;kg] </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">1.28<sup>&#x2021;</sup> </td><td styleCode=\"Rrule\" colspan=\"2\" rowspan=\"2\" valign=\"middle\">  </td></tr><tr><td styleCode=\"Lrule Rrule\" valign=\"middle\">Vz<sup>&#x2020;</sup>[l/kg]<content styleCode=\"bold\"> </content></td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">1.16<sup>&#x2021;</sup> </td></tr></tbody></table>","<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"0\"><colgroup/><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">    <content styleCode=\"bold\">Parameter</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">Cetrorelix Acetate for Injection 3 mg </content> <content styleCode=\"bold\">(sd, active comparator study)</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">Cetrorelix Acetate for Injection 0.25 mg</content> <content styleCode=\"bold\">(md, active comparator study)</content> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\"><content styleCode=\"bold\">Cetrorelix Acetate for Injection 0.25 mg</content> <content styleCode=\"bold\">(md, non-comparative study)</content> </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">No. of subjects </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">115 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">159 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">303 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">hCG administered [%] </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">98.3 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">96.2 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">96.0 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">Oocyte pick-up [%] </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">98.3 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">94.3 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">93.1 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">LH-surge [%] (LH &#x2265; 10 U/L and P* &#x2265; 1 ng/mL)<sup>&#x2020;</sup> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   0.0 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   1.9 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   1.0 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">Serum E<sub>2</sub> [pg/ml] at day hCG<sup>&#x2021;,&#xA7;</sup> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">1125  (470-2952) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">1064  (341-2531) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">1185  (311-3676) </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">Serum LH [U/L] at day hCG<sup>&#x2021;,&#xA7;</sup> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">1.0  (0.5-2.5) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">1.5  (0.5-7.6) </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">1.1  (0.5-3.5) </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">No. of follicles &#x2265; 11 mm at day hCG<sup>&#xB6;</sup> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">11.2&#xB1;5.5 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">10.8&#xB1;5.2 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"middle\">10.4&#xB1;4.5 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">No. of oocytes: IVF<sup>&#xB6;</sup>  ICSI<sup>&#xB6;</sup> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">9.2&#xB1;5.2  10.0&#xB1;4.2 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">7.6&#xB1;4.3  10.1&#xB1;5.6 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">8.5&#xB1;5.1  9.3&#xB1;5.9 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">Fertilization rate: IVF<sup>&#xB6;</sup>   ICSI<sup>&#xB6;</sup> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">0.48&#xB1;0.33  0.66&#xB1;0.29 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">0.62&#xB1;0.26  0.63&#xB1;0.29 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">0.60&#xB1;0.26  0.61&#xB1;0.25 </td></tr><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\">No. of embryos transferred<sup>&#xB6;</sup> </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">2.6&#xB1;0.9 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">2.1&#xB1;0.6 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">2.7&#xB1;1.0 </td></tr><tr><td styleCode=\"Lrule Rrule\" valign=\"top\">Clinical pregnancy rate   [%] per attempt   per subject with ET </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   22.6  26.3 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   20.8  24.1 </td><td styleCode=\"Rrule\" align=\"center\" valign=\"top\">   19.8  23.3 </td></tr></tbody></table>"],"package_label_principal_display_panel":["PACKAGE LABEL.PRINCIPAL DISPLAY PANEL Carton Label NDC 68083-600-01 Rx only Cetrorelix Acetate for Injection 0.25 mg/vial FOR SUBCUTANEOUS USE ONLY STERILE Tray Label Cetrorelix Acetate for Injection 0.25 mg/vial FOR SUBCUTANEOUS USE ONLY STERILE Vial Label NDC 68083-598-01 Cetrorelix Acetate for Injection 0.25 mg/vial STERILE-FOR SUBCUTANEOUS USE ONLY Rx only Single-Dose Vial Syringe Label NDC 68083-599-01 Rx only 1 mL Prefilled Sterile Water for Injection, USP cetro-spl-principle-carton cetro-spl-tray-label cetro-spl-vial-label cetro-spl-pfs-label"]},"tags":[{"label":"Gonadotropin Releasing Hormone Receptor Antagonist","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Gonadotropin-releasing hormone receptor","category":"target"},{"label":"GNRHR","category":"gene"},{"label":"LHCGR","category":"gene"},{"label":"H01CC02","category":"atc"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Mature","category":"status"},{"label":"Premature Luteinizing Hormone Surges","category":"indication"},{"label":"Prevention of premature ovulation","category":"indication"},{"label":"Prevention of premature ovulation during controlled ovarian stimulation","category":"indication"},{"label":"Emd Serono Inc","category":"company"},{"label":"Approved 2000s","category":"decade"},{"label":"Fertility Agents, Female","category":"pharmacology"},{"label":"Hormone Antagonists","category":"pharmacology"},{"label":"Reproductive Control Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"OVARIAN HYPERSTIMULATION SYNDROME","source":"FDA FAERS","actionTaken":"156 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"42 reports"},{"date":"","signal":"PREMATURE OVULATION","source":"FDA FAERS","actionTaken":"40 reports"},{"date":"","signal":"ABORTION SPONTANEOUS","source":"FDA FAERS","actionTaken":"39 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"35 reports"},{"date":"","signal":"ABDOMINAL DISTENSION","source":"FDA FAERS","actionTaken":"28 reports"},{"date":"","signal":"ABDOMINAL PAIN","source":"FDA FAERS","actionTaken":"28 reports"},{"date":"","signal":"ASCITES","source":"FDA FAERS","actionTaken":"28 reports"},{"date":"","signal":"CONDITION AGGRAVATED","source":"FDA FAERS","actionTaken":"25 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"25 reports"}],"commonSideEffects":[{"effect":"Ovarian hyperstimulation syndrome","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Premature ovulation","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Blood luteinising hormone increased","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Ascites","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Abortion spontaneous","drugRate":"","severity":"common","_validated":false,"_confidence":0.3}],"contraindications":["Acute nephropathy","Breastfeeding (mother)","Pregnancy, function"]},"trials":[],"aliases":[],"company":"Merck KGaA","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=CETRORELIX","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:20:52.898092+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:20:58.478568+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T00:20:52.967258+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:20:52.022077+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CETRORELIX","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:20:58.862228+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:20:50.119919+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:21:00.405346+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Gonadotropin-releasing hormone receptor antagonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:20:59.996954+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2103735/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:20:59.657631+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA218150","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:20:50.119948+00:00"}},"allNames":"cetrotide","offLabel":[],"synonyms":["cetrotide","cetrorelix acetate","cetrorelix"],"timeline":[{"date":"1999-04-12","type":"positive","source":"DrugCentral","milestone":"EMA approval (Merck Europe B.V.)"},{"date":"2000-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from EMD SERONO INC to Emd Serono Inc"},{"date":"2000-08-11","type":"positive","source":"DrugCentral","milestone":"FDA approval (Emd Serono Inc)"},{"date":"2006-04-20","type":"positive","source":"DrugCentral","milestone":"PMDA approval (Nippon Kayaku Co., Ltd.)"},{"date":"2024-04-16","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 4 manufacturers approved"}],"approvals":[{"date":"1999-04-12","orphan":false,"company":"MERCK EUROPE B.V.","regulator":"EMA"},{"date":"2000-08-11","orphan":false,"company":"EMD SERONO INC","regulator":"FDA"},{"date":"2006-04-20","orphan":false,"company":"NIPPON KAYAKU CO., LTD.","regulator":"PMDA"}],"brandName":"Cetrotide","ecosystem":[{"indication":"Premature Luteinizing Hormone Surges","otherDrugs":[],"globalPrevalence":null},{"indication":"Prevention of premature ovulation","otherDrugs":[{"name":"nafarelin","slug":"nafarelin","company":"Gd Searle Llc"}],"globalPrevalence":null},{"indication":"Prevention of premature ovulation during controlled ovarian stimulation","otherDrugs":[{"name":"dydrogesterone","slug":"dydrogesterone","company":"Solvay"},{"name":"medroxyprogesterone","slug":"medroxyprogesterone","company":"Pharmacia And Upjohn"}],"globalPrevalence":null}],"mechanism":{"target":"Gonadotropin-releasing hormone receptor","novelty":"Follow-on","targets":[{"gene":"GNRHR","source":"DrugCentral","target":"Gonadotropin-releasing hormone receptor","protein":"Gonadotropin-releasing hormone receptor"},{"gene":"LHCGR","source":"DrugCentral","target":"Lutropin-choriogonadotropic hormone receptor","protein":"Lutropin-choriogonadotropic hormone receptor"}],"moaClass":"Gonadotropin Releasing Hormone Receptor Antagonists","modality":"Small Molecule","drugClass":"Gonadotropin Releasing Hormone Receptor Antagonist","explanation":"","oneSentence":"","technicalDetail":"Cetrotide is a competitive antagonist of the gonadotropin-releasing hormone receptor, specifically binding to the receptor and preventing the action of gonadotropin-releasing hormone, which normally stimulates the release of luteinizing hormone and follicle-stimulating hormone."},"commercial":{"launchDate":"2000","_launchSource":"DrugCentral (FDA 2000-08-11, EMD SERONO INC)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/583","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=CETRORELIX","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CETRORELIX","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T09:31:33.765044","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:21:02.494848+00:00","fieldsConflicting":6,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"ganirelix","drugSlug":"ganirelix","fdaApproval":"1999-07-29","genericCount":7,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"elagolix","drugSlug":"elagolix","fdaApproval":"2018-07-23","patentExpiry":"Sep 1, 2036","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"estradiol","drugSlug":"estradiol","fdaApproval":"1975-07-23","patentExpiry":"Nov 21, 2032","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"norethisterone","drugSlug":"norethisterone","fdaApproval":"1962-05-21","relationship":"same-class"},{"drugName":"relugolix","drugSlug":"relugolix","fdaApproval":"2020-12-18","patentExpiry":"Sep 29, 2037","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"cetrorelix","indications":{"approved":[{"name":"Premature Luteinizing Hormone Surges","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Prevention of premature ovulation","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Prevention of premature ovulation during controlled ovarian stimulation","source":"DrugCentral","snomedId":732970000,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"currentOwner":"Emd Serono Inc","drugCategory":"mature","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"ganirelix","brandName":"ganirelix","genericName":"ganirelix","approvalYear":"1999","relationship":"same-class"},{"drugId":"elagolix","brandName":"elagolix","genericName":"elagolix","approvalYear":"2018","relationship":"same-class"},{"drugId":"estradiol","brandName":"estradiol","genericName":"estradiol","approvalYear":"1975","relationship":"same-class"},{"drugId":"norethisterone","brandName":"norethisterone","genericName":"norethisterone","approvalYear":"1962","relationship":"same-class"},{"drugId":"relugolix","brandName":"relugolix","genericName":"relugolix","approvalYear":"2020","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT06378268","phase":"NA","title":"PPOS vs GnRH Antagonist in Ovarian Stimulation (ProGanOS Study)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mỹ Đức Hospital","startDate":"2024-04-24","conditions":["Progestins Primed Ovarian Stimulation"],"enrollment":626,"completionDate":"2026-09-30"},{"nctId":"NCT07340827","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA)","status":"RECRUITING","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","startDate":"2026-02-05","conditions":["Infertility"],"enrollment":333,"completionDate":"2029-06-30"},{"nctId":"NCT05326087","phase":"PHASE3","title":"Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Women With PCOS Undergoing PGT-A","status":"NOT_YET_RECRUITING","sponsor":"ShangHai Ji Ai Genetics & IVF Institute","startDate":"2026-06-01","conditions":["Preimplantation Genetic Testing","Progestin-primed Ovarian Stimulation","Polycystic Ovarian Syndrome","GnRH Antagonist"],"enrollment":204,"completionDate":"2028-12-01"},{"nctId":"NCT07350317","phase":"PHASE4","title":"Trial Comparing Subcutaneous Natural Progesterone (Prolutex) vs. Cetrorelix Acetate for Luteinizing Hormone Surge Suppression in Freeze-All IVF Cycles.","status":"NOT_YET_RECRUITING","sponsor":"Trust Fertility Clinic","startDate":"2026-01","conditions":["Assisted Reproductive Techniques"],"enrollment":230,"completionDate":"2027-02"},{"nctId":"NCT02892942","phase":"PHASE4","title":"NATural Ovarian Stimulation","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-01-13","conditions":["Infertility"],"enrollment":129,"completionDate":"2019-02-08"},{"nctId":"NCT06023602","phase":"NA","title":"Effectiveness of Generic Versus Reference Cetrorelix Acetate for Ovarian Stimulation Using a Gonadotropin-releasing Hormone（GnRH）Antagonist Protocol in Women Undergoing IVF","status":"RECRUITING","sponsor":"Northwest Women's and Children's Hospital, Xi'an, Shaanxi","startDate":"2024-02-27","conditions":["Infertility"],"enrollment":1338,"completionDate":"2025-12-01"},{"nctId":"NCT03680053","phase":"NA","title":"Comparison of the Live Birth Rate Between the PPOS and the GnRH Antagonist Protocol in Patients Undergoing IVF","status":"TERMINATED","sponsor":"ShangHai Ji Ai Genetics & IVF Institute","startDate":"2020-04-10","conditions":["Infertility","ART"],"enrollment":220,"completionDate":"2025-05-10"},{"nctId":"NCT04414748","phase":"PHASE3","title":"Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Patients Undergoing PGT-A","status":"COMPLETED","sponsor":"ShangHai Ji Ai Genetics & IVF Institute","startDate":"2020-06-10","conditions":["Preimplantation Genetic Testing","Progestin-primed Ovarian Stimulation","Euploid Rate","GnRH Antagonist"],"enrollment":400,"completionDate":"2025-05-27"},{"nctId":"NCT06868576","phase":"PHASE3","title":"PPOS Protocol Versus GnRH Anatagonist for Expected Normal Responder Patients Undergoing ART : a Randomized Clinical Trial","status":"COMPLETED","sponsor":"Kasr El Aini Hospital","startDate":"2023-01-03","conditions":["PPOS","GnRH Antagonist","Assisted Reproductive Techniques"],"enrollment":328,"completionDate":"2025-02-28"},{"nctId":"NCT02496754","phase":"NA","title":"Follicular Long GnRH Agonist Versus Antagonist Protocol in PCOS Women Undergoing in Vitro Fertilization","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2016-06","conditions":["Clinical Pregnancy Rate","Ovulation Induction","IVF"],"enrollment":1266,"completionDate":"2024-12"},{"nctId":"NCT06812559","phase":"","title":"Progesterone Primed Ovarian Stimulation Versus GnRH Antagonist Protocols in Women With Polycystic Ovarian Syndrome","status":"COMPLETED","sponsor":"El Shatby University Hospital for Obstetrics and Gynecology","startDate":"2023-12-01","conditions":["Controlled Ovarian Hyperstimulation","Polycystic Ovarian Syndrome"],"enrollment":100,"completionDate":"2025-02-01"},{"nctId":"NCT06572930","phase":"","title":"Serum FSH Monitoring for Identification of an Optimal Range During Ovarian Stimulation","status":"RECRUITING","sponsor":"ART Fertility Clinics LLC","startDate":"2024-12-16","conditions":["Ovarian Stimulation"],"enrollment":150,"completionDate":"2025-12-01"},{"nctId":"NCT05447208","phase":"PHASE3","title":"Effect of GH on the Blastocyst Euploid Rate in AMA Patients","status":"RECRUITING","sponsor":"ShangHai Ji Ai Genetics & IVF Institute","startDate":"2022-08-01","conditions":["Preimplantation Genetic Testing","Growth Hormone","Age, Parental"],"enrollment":400,"completionDate":"2026-12-31"},{"nctId":"NCT06608186","phase":"PHASE1,PHASE2","title":"Can Drospirenone be Used to Prevent LH Surge in Controlled Ovarian Stimulation in PCOS?!","status":"COMPLETED","sponsor":"Ahmed Saad","startDate":"2024-10-01","conditions":["PCOS (Polycystic Ovary Syndrome)"],"enrollment":50,"completionDate":"2025-01-19"},{"nctId":"NCT06778733","phase":"EARLY_PHASE1","title":"Effectiveness of Low Dose Gonadotropin Stimulation Protocol Vs High Dose Gonadotropin Protocol in Poor Responders","status":"COMPLETED","sponsor":"University of Athens","startDate":"2022-01-01","conditions":["Female Infertility"],"enrollment":22,"completionDate":"2024-04-30"},{"nctId":"NCT05767086","phase":"NA","title":"Comparison of 3 Different Protocols for Preventing Premature Ovulation in Ovarian Stimulation Cycles","status":"COMPLETED","sponsor":"Bezmialem Vakif University","startDate":"2023-03-15","conditions":["Infertility"],"enrollment":297,"completionDate":"2024-09-30"},{"nctId":"NCT06571214","phase":"PHASE4","title":"Potential Benefit of r-hLH Addition in Patients Aged 35 to 40 Under Ovarian Stimulation Treatment","status":"NOT_YET_RECRUITING","sponsor":"Nanjing University","startDate":"2024-09-01","conditions":["Infertility"],"enrollment":300,"completionDate":"2027-01-30"},{"nctId":"NCT02890082","phase":"PHASE2","title":"Preservation of Fertility by Ovarian Stimulation Associated With Tamoxifen, Prior Chemotherapy for Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut Cancerologie de l'Ouest","startDate":"2014-02","conditions":["Breast Cancer"],"enrollment":102,"completionDate":"2028-01"},{"nctId":"NCT06396390","phase":"PHASE4","title":"Comparison of Progestin Primed Ovarian Stimulation (PPOS) vs.GnRH Antagonist Methods on IVF Outcomes","status":"NOT_YET_RECRUITING","sponsor":"Nesta Clinic","startDate":"2024-08-01","conditions":["IVF","Fertility Issues","Infertility"],"enrollment":152,"completionDate":"2026-08-01"},{"nctId":"NCT02478775","phase":"NA","title":"Dysregulation of FSH in Obesity: Functional and Statistical Analysis","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2015-07","conditions":["Obesity","Fertility"],"enrollment":99,"completionDate":"2021-06-30"},{"nctId":"NCT04719000","phase":"PHASE4","title":"PErsonalized Addition of Recombinant LH in Ovarian Stimulation","status":"RECRUITING","sponsor":"Fundación Santiago Dexeus Font","startDate":"2021-02-04","conditions":["Infertility"],"enrollment":120,"completionDate":"2025-11"},{"nctId":"NCT03809429","phase":"PHASE3","title":"Follitropin Delta in Long GnRH Agonist and GnRH Antagonist Protocols (BEYOND)","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2019-04-29","conditions":["Infertility, Female"],"enrollment":437,"completionDate":"2022-02-16"},{"nctId":"NCT06297564","phase":"NA","title":"Progesterone Primed Endometrial Protocol Versus Gonadotropin-releasing Hormone Antagonist Protocol in Assisted Reproductive Treatments","status":"COMPLETED","sponsor":"New Valley University","startDate":"2022-09-01","conditions":["Progesterone Primed Endometrial Protocol","Gonadotropin Releasing Hormone Antagonist Protocol","Assisted Reproductive Treatments"],"enrollment":40,"completionDate":"2024-01-01"},{"nctId":"NCT04989348","phase":"NA","title":"Euploid Rate of Blastocyst Derived From PPOS VS Antagonist Protocol","status":"COMPLETED","sponsor":"Shanghai First Maternity and Infant Hospital","startDate":"2021-08-04","conditions":["IVF"],"enrollment":240,"completionDate":"2024-02-20"},{"nctId":"NCT04671966","phase":"PHASE4","title":"Sex Differences in Myocardial Steatosis Induced Left Ventricular Dysfunction","status":"UNKNOWN","sponsor":"The University of Texas at Arlington","startDate":"2018-09-13","conditions":["Heart Diseases","Left Ventricular Dysfunction"],"enrollment":100,"completionDate":"2024-12"},{"nctId":"NCT06212102","phase":"PHASE2","title":"Dydrogesterone Versus GnRH Antagonist in Poor Responders Undergoing Double Ovarian Stimulation","status":"NOT_YET_RECRUITING","sponsor":"Bedaya Hospital","startDate":"2024-02","conditions":["Infertility"],"enrollment":120,"completionDate":"2026-12"},{"nctId":"NCT06199960","phase":"PHASE3","title":"Dual Ovarian Stimulation (Duostim) and Shanghai Protocols in Poor Ovarian Responders","status":"COMPLETED","sponsor":"Royan Institute","startDate":"2019-08-02","conditions":["Assisted Reproductive Techniques"],"enrollment":116,"completionDate":"2023-11-20"},{"nctId":"NCT06191809","phase":"NA","title":"Evaluate the Effectiveness of Progestin-Primed Versus GnRH Antagonist Protocols in Vietnamese Women Undergoing In-vitro Fertilization","status":"UNKNOWN","sponsor":"Hanoi Medical University","startDate":"2023-02-14","conditions":["IVF"],"enrollment":200,"completionDate":"2024-12-31"},{"nctId":"NCT04724486","phase":"PHASE4","title":"Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology During IVF/ICSI","status":"COMPLETED","sponsor":"Damascus University","startDate":"2020-08-22","conditions":["In Vitro Fertilization","Intracytoplasmic Sperm Injection","Infertility"],"enrollment":50,"completionDate":"2022-07-15"},{"nctId":"NCT04724343","phase":"PHASE4","title":"Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes.","status":"COMPLETED","sponsor":"Damascus University","startDate":"2019-12-22","conditions":["In Vitro Fertilization","Intracytoplasmic Sperm Injection","Infertility"],"enrollment":50,"completionDate":"2022-07-05"},{"nctId":"NCT04727684","phase":"PHASE4","title":"Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology in Polycystic Ovary Syndrome Patients During IVF/ICSI","status":"COMPLETED","sponsor":"Damascus University","startDate":"2020-08-22","conditions":["In Vitro Fertilization","Infertility","Intracytoplasmic Sperm Injection","Polycystic Ovary Syndrome"],"enrollment":50,"completionDate":"2022-05-12"},{"nctId":"NCT04727671","phase":"PHASE4","title":"Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes in Polycystic Ovary Syndrome Patients.","status":"COMPLETED","sponsor":"Damascus University","startDate":"2019-12-22","conditions":["In Vitro Fertilization","Intracytoplasmic Sperm Injection","Infertility","Polycystic Ovary Syndrome"],"enrollment":50,"completionDate":"2021-12-30"},{"nctId":"NCT04447872","phase":"NA","title":"The LUTEAL Trial: Luteal Stimulation vs. Estrogen Priming Protocol","status":"UNKNOWN","sponsor":"Northwell Health","startDate":"2020-09-15","conditions":["Infertility","Diminished Ovarian Reserve","IVF"],"enrollment":142,"completionDate":"2025-06"},{"nctId":"NCT04414761","phase":"PHASE3","title":"Live Birth Rate Between PPOS and GnRH Antagonist Protocol in Patients With Anticipated High Ovarian Response","status":"COMPLETED","sponsor":"ShangHai Ji Ai Genetics & IVF Institute","startDate":"2020-06-04","conditions":["IVF","GnRH Antagonist","PPOS"],"enrollment":784,"completionDate":"2022-10-10"},{"nctId":"NCT05951400","phase":"PHASE2,PHASE3","title":"Progesterone Primed Ovarian Stimulation Versus GnRH Antagonist in With Expected High Ovarian Response Undergoing in Vitro Fertilization","status":"UNKNOWN","sponsor":"Beni-Suef University","startDate":"2023-08-20","conditions":["IVF","PCO"],"enrollment":200,"completionDate":"2023-09-30"},{"nctId":"NCT05972902","phase":"PHASE3","title":"Dydrogesterone, Cetrorelix Acetate and Triptorelin in Intra Cytoplasmic Sperm Injection Outcomes","status":"UNKNOWN","sponsor":"Beni-Suef University","startDate":"2023-07-15","conditions":["IVF"],"enrollment":387,"completionDate":"2023-12-31"},{"nctId":"NCT05738382","phase":"PHASE2","title":"Efficacy and Safety of BG2109 During Controlled Ovarian Hyperstimulation in Female Subjects Undergoing ART Procedures","status":"UNKNOWN","sponsor":"Bio Genuine (Shanghai) Biotech Co., Ltd.","startDate":"2023-08","conditions":["Assisted Reproductive Technology","Controlled Ovarian Hyperstimulation"],"enrollment":240,"completionDate":"2024-12"},{"nctId":"NCT04157725","phase":"PHASE4","title":"Mild Stimulation Protocol Using Clomiphene Citrate for Women With PCOS Undergoing in Vitro Fertilization","status":"UNKNOWN","sponsor":"American University of Beirut Medical Center","startDate":"2023-06-01","conditions":["PCO - Polycystic Ovaries","Infertility"],"enrollment":154,"completionDate":"2025-07-01"},{"nctId":"NCT04754243","phase":"PHASE4","title":"New Protocol in Unexplained Infertility","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2021-03-01","conditions":["Unexplained Infertility"],"enrollment":200,"completionDate":"2024-12-31"},{"nctId":"NCT05900661","phase":"PHASE2,PHASE3","title":"The Effect of Myo-inositol, Somatropin, and DHEA on Poor Ovarian Responders","status":"UNKNOWN","sponsor":"Beni-Suef University","startDate":"2023-07-30","conditions":["Poor Responders"],"enrollment":300,"completionDate":"2023-09-30"},{"nctId":"NCT05939284","phase":"NA","title":"Progesterone-Primed Ovarian Simulation in Controlled-ovarian Simulation of Infertile PCOS Patients","status":"COMPLETED","sponsor":"Zagazig University","startDate":"2021-06-01","conditions":["PCOS"],"enrollment":238,"completionDate":"2023-01-25"},{"nctId":"NCT04931355","phase":"NA","title":"Acupuncture in the Freeze-all IVF Cycle","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2023-06-01","conditions":["Acupuncture","Female Infertility"],"enrollment":90,"completionDate":"2024-12-30"},{"nctId":"NCT04616729","phase":"PHASE1,PHASE2","title":"DEPO-Trigger Trial: GnRH Agonist DEPOt TRIGGER for Final Oocyte Maturation","status":"UNKNOWN","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2022-11-01","conditions":["Breast Cancer Female"],"enrollment":30,"completionDate":"2025-12-31"},{"nctId":"NCT04108039","phase":"NA","title":"Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles.","status":"COMPLETED","sponsor":"Fundacion Dexeus","startDate":"2019-09-25","conditions":["Infertility","IVF","Preimplantation Diagnosis"],"enrollment":44,"completionDate":"2022-05-15"},{"nctId":"NCT02912988","phase":"PHASE3","title":"Letrozole in Stimulated IVF Cycles","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2018-03-01","conditions":["Subfertility"],"enrollment":900,"completionDate":"2023-04-30"},{"nctId":"NCT04071574","phase":"PHASE1,PHASE2","title":"Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility","status":"COMPLETED","sponsor":"Lebanese University","startDate":"2018-02-01","conditions":["Female Infertility","Female Infertility Due to Ovulatory Disorder","Premature Ovarian Failure","Polycystic Ovary Syndrome","Female Infertility of Tubal Origin","Ectopic Pregnancy","Salpingitis","Female Infertility Due to Tubal Block","Female Infertility Due to Tubal Occlusion","Hydrosalpinx","Female Infertility - Cervical/Vaginal","Female Infertility Endocrine","Endometriosis","Fibroids","Congenital Uterine Anomaly","Infections Uterine","Female Infertility of Other Origin"],"enrollment":200,"completionDate":"2023-05-05"},{"nctId":"NCT05847660","phase":"NA","title":"Progesterone Primed Ovarian Stimulation Protocol Versus Antagonist Protocol for PCO Patient","status":"UNKNOWN","sponsor":"Fayoum University","startDate":"2023-06-01","conditions":["Polycystic Ovary Syndrome","Infertility","IVF"],"enrollment":210,"completionDate":"2024-07-01"},{"nctId":"NCT05778331","phase":"","title":"The Difference Between POSEIDON Group 3 and Group 4 as Regards IVF","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2023-01-10","conditions":["Infertility, Female","IVF"],"enrollment":340,"completionDate":"2023-09"},{"nctId":"NCT05751681","phase":"NA","title":"Dydrogesterone-Primed Ovarian Stimulation Protocol Versus Gonadotropin Releasing Hormone Antagonist Protocol in ICSI","status":"UNKNOWN","sponsor":"Zagazig University","startDate":"2023-02-20","conditions":["Ovary Cyst","Fertility Issues"],"enrollment":79,"completionDate":"2025-03-20"},{"nctId":"NCT05577806","phase":"","title":"DYG Versus Cetrorelix in Oocyte Donation","status":"COMPLETED","sponsor":"Clinica de la Mujer Medicina Reproductiva, Chile","startDate":"2017-01-01","conditions":["Infertility, Female","Fertility Disorders"],"enrollment":202,"completionDate":"2021-12-31"},{"nctId":"NCT04052607","phase":"NA","title":"Progestin Priming Ovarian Stimulation (PPOS) Compared With Antagonist Protocol for Freeze-all Cycles","status":"TERMINATED","sponsor":"Ibn Sina Hospital","startDate":"2019-09-10","conditions":["Infertility"],"enrollment":56,"completionDate":"2020-04-30"},{"nctId":"NCT04537078","phase":"PHASE3","title":"Progestin Primed Double Stimulation Protocol Versus Flexible GnRH Antagonist Protocol in Poor Responders","status":"COMPLETED","sponsor":"El Shatby University Hospital for Obstetrics and Gynecology","startDate":"2020-09-01","conditions":["Infertility, Female"],"enrollment":90,"completionDate":"2021-09-01"},{"nctId":"NCT02195947","phase":"PHASE4","title":"Antagonist Protocol in Poor Responders","status":"COMPLETED","sponsor":"Cairo University","startDate":"2014-07","conditions":["Female Infertility Due to Diminished Ovarian Reserve"],"enrollment":141,"completionDate":"2015-07"},{"nctId":"NCT05112692","phase":"NA","title":"Progestin-primed Ovarian Stimulation Protocol Versus GnRH Antagonist Protocol in Polycystic Ovary Syndrome Patients Undergoing IVF/ICSI Cycles","status":"UNKNOWN","sponsor":"Mansoura University","startDate":"2021-11","conditions":["PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries"],"enrollment":200,"completionDate":"2023-12"},{"nctId":"NCT04854707","phase":"","title":"An Observational Study of Follitropin Alpha Biosimilar: the Real-world Data","status":"COMPLETED","sponsor":"IVFarma LLC","startDate":"2020-01-12","conditions":["Reproductive Issues","Reproductive Disorder","Fertility Disorders","Fertility Issues","Gynecologic Disease","IVF"],"enrollment":5484,"completionDate":"2021-01-20"},{"nctId":"NCT04993924","phase":"PHASE4","title":"GnRH Antagonist Pre-treatment in the Early Follicular Phase for Resolution of a Baseline Functional Ovarian Cyst","status":"UNKNOWN","sponsor":"Assaf-Harofeh Medical Center","startDate":"2021-05-01","conditions":["IVF","Ovarian Cysts"],"enrollment":15,"completionDate":"2023-03-01"},{"nctId":"NCT05071339","phase":"PHASE4","title":"GnRH Antagonist Pre-treatment for the Prevention of Asynchronous Follicular Growth","status":"UNKNOWN","sponsor":"Assaf-Harofeh Medical Center","startDate":"2021-04-01","conditions":["IVF"],"enrollment":15,"completionDate":"2023-03-01"},{"nctId":"NCT04935073","phase":"PHASE3","title":"Traditional Chinese Medicine Herbs in the Freeze-all IVF Cycle","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2021-06-15","conditions":["Infertility, Female"],"enrollment":90,"completionDate":"2022-12-30"},{"nctId":"NCT04842825","phase":"PHASE3","title":"Sequential Therapy of TCM Herbs to Improve the Success Rate of IVF-ET in Diminished Ovarian Reserve Patients","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2021-04-15","conditions":["Infertility, Female"],"enrollment":200,"completionDate":"2022-12-30"},{"nctId":"NCT03876145","phase":"NA","title":"The Four Methods of Ovarian Stimulation in Patients With Polycystic Ovarian Syndrome","status":"COMPLETED","sponsor":"Royan Institute","startDate":"2016-11-12","conditions":["Polycystic Ovary Syndrome","Ovarian Hyperstimulation Syndrome"],"enrollment":120,"completionDate":"2020-11-20"},{"nctId":"NCT04819204","phase":"NA","title":"Testosterone and Neurovascular Control in Humans","status":"UNKNOWN","sponsor":"Western University, Canada","startDate":"2021-06","conditions":["Healthy"],"enrollment":20,"completionDate":"2023-12"},{"nctId":"NCT03291821","phase":"NA","title":"DuoStim in Cases of PGT: Comparison of Embryo Quantity and Embryonic Quality Using MitoScore","status":"COMPLETED","sponsor":"IVI Madrid","startDate":"2017-12-01","conditions":["Infertility, Female"],"enrollment":136,"completionDate":"2020-06-01"},{"nctId":"NCT04418908","phase":"NA","title":"Estrogen, Diabetes, and Endothelial Function","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2010-11-24","conditions":["Type 1 Diabetes"],"enrollment":40,"completionDate":"2018-10-22"},{"nctId":"NCT03373149","phase":"PHASE2","title":"Growth Hormone Co-treatment Within a GnRH Antagonist Protocol in Patients With Poor Ovarian Response","status":"UNKNOWN","sponsor":"Riyadh Fertility and Reproductive Health center","startDate":"2017-11-29","conditions":["Infertility, Female"],"enrollment":228,"completionDate":"2020-11"},{"nctId":"NCT04094467","phase":"PHASE4","title":"Comparison Between Two Different Protocols in Polycystic Ovary Symdrome Women Undergoing Intra-cytoplasmic Injection","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2019-12-07","conditions":["Polycystic Ovary Syndrome"],"enrollment":150,"completionDate":"2021-01"},{"nctId":"NCT04308343","phase":"NA","title":"The Aromatase Inhibitor and Gnrh Antagonist Versus Methotrexate for Management of Undisturbed Ectopic Pregnancy","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2020-03-30","conditions":["Ectopic Pregnancy"],"enrollment":120,"completionDate":"2022-09-01"},{"nctId":"NCT04268927","phase":"PHASE2","title":"Extended Letrozole Regimen Co-treatment With Gonadotropin Releasing Hormone Antagonist Protocol Versus Gonadotropin Releasing Hormone Antagonist Protocol in Poor Responders Undergoing IVF-ET","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2018-04-01","conditions":["Infertility"],"enrollment":106,"completionDate":"2020-04-20"},{"nctId":"NCT03181685","phase":"PHASE4","title":"Patients' Preference for Subcutaneous or Vaginal Progesterone as Luteal Support in IVF/ICSI Cycles","status":"TERMINATED","sponsor":"Andros Day Surgery Clinic","startDate":"2016-12-20","conditions":["Infertility","In Vitro Fertilization"],"enrollment":60,"completionDate":"2019-12"},{"nctId":"NCT02889380","phase":"","title":"A Retrospective Study in Chinese Good Prognosis Patients Undergoing Assisted Reproductive Technology (ART) Treatment","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2016-08-29","conditions":["Infertility"],"enrollment":3000,"completionDate":"2017-04-26"},{"nctId":"NCT03996434","phase":"PHASE4","title":"Coasting Versus Antagonist Protocol in Patients at High Risk of OHSS","status":"COMPLETED","sponsor":"ClinAmygate","startDate":"2019-07-01","conditions":["Ovarian Hyperstimulation Syndrome"],"enrollment":300,"completionDate":"2019-11-20"},{"nctId":"NCT04026282","phase":"NA","title":"To Investigate the Cumulative Live Birth Rates Using GnRH Antagonist or Agonist Protocol for COS in ART Treatment","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2018-12-27","conditions":["Sterility"],"enrollment":888,"completionDate":"2022-07-31"},{"nctId":"NCT02821819","phase":"PHASE4","title":"Random-start Ovarian Stimulation in Egg-donors (ROSE)","status":"TERMINATED","sponsor":"Instituto Bernabeu","startDate":"2017-01-10","conditions":["Infertility"],"enrollment":15,"completionDate":"2018-01-12"},{"nctId":"NCT02042196","phase":"EARLY_PHASE1","title":"Sex Hormones and Atherosclerosis Prevention in Perimenopausal Women","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2013-12","conditions":["Menopause","Aging"],"enrollment":100,"completionDate":"2016-05-02"},{"nctId":"NCT04008966","phase":"PHASE4","title":"Comparative Study Between Single Versus Dual Trigger for Poor Responders in GnRH-antagonist ICSI Cycles","status":"COMPLETED","sponsor":"Cairo University","startDate":"2016-07-20","conditions":["Assisted Reproduction"],"enrollment":160,"completionDate":"2019-07-01"},{"nctId":"NCT03759301","phase":"PHASE4","title":"Efficacy of Growth Hormone Supplementation With Gonadotrophins in IVF/ICSI for Poor Responders","status":"COMPLETED","sponsor":"ClinAmygate","startDate":"2018-12-20","conditions":["Infertility, Female"],"enrollment":156,"completionDate":"2019-06-05"},{"nctId":"NCT03763786","phase":"PHASE4","title":"Frozen Embryo Transfer With GnRH-antagonist Trial","status":"UNKNOWN","sponsor":"University of Oxford","startDate":"2018-12-13","conditions":["Infertility"],"enrollment":300,"completionDate":"2021-01"},{"nctId":"NCT02625532","phase":"NA","title":"Early Follicular Phase vs Lutheal Phase Ovarian Stimulation in Bologna Criteria IVF/ICSI Cycles (LUTEAL Trial)","status":"UNKNOWN","sponsor":"Instituto Bernabeu","startDate":"2015-12","conditions":["Reproductive Techniques, Assisted"],"enrollment":60,"completionDate":"2019-01"},{"nctId":"NCT01112358","phase":"PHASE2","title":"Lutropin Alfa in Women at Risk of Poor Response","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2005-12-07","conditions":["Ovarian Stimulation"],"enrollment":58,"completionDate":"2007-01-30"},{"nctId":"NCT00449150","phase":"PHASE3","title":"Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)","status":"TERMINATED","sponsor":"AEterna Zentaris","startDate":"2007-03","conditions":["Benign Prostatic Hypertrophy"],"enrollment":667,"completionDate":"2009-12"},{"nctId":"NCT03484611","phase":"NA","title":"Prediction of Metaphase II Oocytes According to Different Levels of Serum AMH in Poor Responders Using the Antagonist Protocol","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2013-01","conditions":["Invitro Fertilizaion"],"enrollment":179,"completionDate":"2018-04"},{"nctId":"NCT03477929","phase":"PHASE4","title":"Cetrorelix and Ganirelix Flexible Protocol for (IVF)","status":"UNKNOWN","sponsor":"Università degli Studi 'G. d'Annunzio' Chieti e Pescara","startDate":"2017-11-15","conditions":["Infertility/Sterility"],"enrollment":100,"completionDate":"2019-01-15"},{"nctId":"NCT03457233","phase":"NA","title":"The Impact of Body Weight on Reproductive Outcomes in Poor Ovarian Responders in ICSI Cycles","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2015-01-03","conditions":["Invitro Fertilization"],"enrollment":185,"completionDate":"2018-03"},{"nctId":"NCT03118830","phase":"PHASE4","title":"Long Protocol and Freeze All Embryos vs Antagonist Protocol With Fresh Embryo Transfer in PCOS Patients Undergoing ICSI","status":"COMPLETED","sponsor":"Cairo University","startDate":"2017-04-21","conditions":["Invitro Fertilization"],"enrollment":204,"completionDate":"2017-11-03"},{"nctId":"NCT01402336","phase":"PHASE3","title":"GnRH Antagonist Versus GnRH Agonist in Polycystic Ovary Syndrome During in Vitro Fertilization - Embryo Transfer","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2011-06","conditions":["Infertility","Polycystic Ovary Syndrome"],"enrollment":43,"completionDate":"2016-12-31"},{"nctId":"NCT03139474","phase":"PHASE2,PHASE3","title":"Impact of Gonadotrophin Releasing Hormone Analogues on Oocyte and Embryo Quality","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2017-06-01","conditions":["Infertility, Female"],"enrollment":120,"completionDate":"2020-06-01"},{"nctId":"NCT01565265","phase":"NA","title":"Comparing Ovarian Stimulation for Assisted Reproduction With Two Different Forms of Pituitary Suppression","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2012-04","conditions":["Female Infertility Due to Nonimplantation of Ovum","Complications Associated With Artificial Fertilization"],"enrollment":5,"completionDate":"2013-12"},{"nctId":"NCT02823080","phase":"PHASE2,PHASE3","title":"Outcome of Cetrotide Therapy for Management of Women at High-risk of Ovarian Hyperstimulation Syndrome","status":"UNKNOWN","sponsor":"Benha University","startDate":"2014-10","conditions":["Infertility"],"enrollment":48,"completionDate":"2017-05"},{"nctId":"NCT01457703","phase":"NA","title":"Reproductive Hormonal Alterations in Obesity","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2010-06","conditions":["Obesity"],"enrollment":62,"completionDate":"2013-07"},{"nctId":"NCT01590173","phase":"PHASE2,PHASE3","title":"Addition of Prednisolone and Heparin in Patients Undergoing IVF With Failed IVF Cycles","status":"COMPLETED","sponsor":"National and Kapodistrian University of Athens","startDate":"2012-01","conditions":["Infertility"],"enrollment":86,"completionDate":"2016-07"},{"nctId":"NCT02820415","phase":"","title":"PGS on Blastocysts From Vitrified and Fresh Oocytes","status":"COMPLETED","sponsor":"Unità di Medicina della Riproduzione, Italy","startDate":"2014-06","conditions":["Increase the Number of Blastocyst to Biopsy for Preimplantation Genetic Testing"],"enrollment":60,"completionDate":"2015-12"},{"nctId":"NCT01798862","phase":"PHASE2,PHASE3","title":"Endometrial Injury and IVF Outcome Parameters in Patients With Failed IVF Cycles","status":"COMPLETED","sponsor":"National and Kapodistrian University of Athens","startDate":"2013-03","conditions":["Repeated Implantation Failures"],"enrollment":100,"completionDate":"2016-06"},{"nctId":"NCT02784457","phase":"PHASE2","title":"Gonadotropin Releasing Hormone Antagonist in Treatment of Early-onset Severe Ovarian Hyperstimulation Syndrome","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2014-06","conditions":["Assisted Reproduction"],"enrollment":84,"completionDate":"2016-03"},{"nctId":"NCT01709942","phase":"PHASE3","title":"Use of Degarelix in Controlled Ovarian Hyperstimulation (COH) Protocol for Women With PoliCystic Ovarian Syndrome (PCOS)","status":"COMPLETED","sponsor":"Centre for Endocrinology and Reproductive Medicine, Italy","startDate":"2012-11","conditions":["PCOS","OHSS","INFERTILITY"],"enrollment":80,"completionDate":"2015-12"},{"nctId":"NCT01109888","phase":"PHASE1,PHASE2","title":"Administration of Increased Dose of GnRH Antagonist for Coasting for Decreasing the Risk for Ovarian Hyperstimulation Syndrome( OHSS)","status":"WITHDRAWN","sponsor":"Wolfson Medical Center","startDate":"","conditions":["Administration of Increased Dose of GnRH Antagonist for Coasting for Decreasing the Risk for Ovarian Hyperstimulation Syndrome( OHSS)"],"enrollment":0,"completionDate":""},{"nctId":"NCT02335736","phase":"PHASE2","title":"Antagonist Protocol in IVF","status":"UNKNOWN","sponsor":"Woman's Health University Hospital, Egypt","startDate":"2015-01","conditions":["Infertility"],"enrollment":200,"completionDate":"2016-04"},{"nctId":"NCT02333253","phase":"PHASE3","title":"Delayed Start Versus Conventional Antagonist Protocol in Poor Responders Pretreated by Estradiol in Luteal Phase","status":"COMPLETED","sponsor":"Cairo University","startDate":"2015-01","conditions":["Other Complications Associated With Artificial Fertilization"],"enrollment":60,"completionDate":"2016-01"},{"nctId":"NCT02640976","phase":"EARLY_PHASE1","title":"Poor Ovarian Stimulation Response in In Vitro Fertilization (IVF) Program","status":"COMPLETED","sponsor":"Cairo University","startDate":"2013-06","conditions":["Infertility"],"enrollment":216,"completionDate":"2015-08"},{"nctId":"NCT02461875","phase":"PHASE2","title":"Cabergoline Versus GnRH Antagonist Rescue and Cabergoline in the Prevention of Ovarian Hyperstimulation Syndrome","status":"UNKNOWN","sponsor":"Aljazeera Hospital","startDate":"2013-05","conditions":["OHSS"],"enrollment":236,"completionDate":"2015-12"},{"nctId":"NCT01897324","phase":"PHASE4","title":"IVF/ICSI Protocols in Poor Responders With Growth Hormone","status":"COMPLETED","sponsor":"Woman's Health University Hospital, Egypt","startDate":"2013-07","conditions":["Female Infertility Due to Diminished Ovarian Reserve"],"enrollment":287,"completionDate":"2015-01"},{"nctId":"NCT01204840","phase":"PHASE2","title":"Growth Hormone for Poor Responders in in Vitro Fertilization (IVF)","status":"COMPLETED","sponsor":"Ottawa Fertility Centre","startDate":"2010-09","conditions":["Infertility","Poor Ovarian Reserve"],"enrollment":38,"completionDate":"2015-05"}],"_emaApprovals":[{"date":"1999-04-12","status":"Authorised","company":"MERCK EUROPE B.V."}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_patentsChecked":true,"crossReferences":{"MMSL":"15671","NDDF":"007799","UNII":"OON1HFZ4BA","CHEBI":"CHEBI:59224","VANDF":"4021277","INN_ID":"6661","RXNORM":"259338","UMLSCUI":"C0209366","chemblId":"CHEMBL2103735","ChEMBL_ID":"CHEMBL1200490","KEGG_DRUG":"D01685","DRUGBANK_ID":"DB00050","PUBCHEM_CID":"25074887","SNOMEDCT_US":"326083001","IUPHAR_LIGAND_ID":"1190","SECONDARY_CAS_RN":"130143-01-0","MESH_SUPPLEMENTAL_RECORD_UI":"C062876"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2000-","companyName":"Emd Serono Inc","relationship":"Original Developer"},{"period":"1999","companyName":"Merck Europe B.V.","relationship":"EMA Licensee"},{"period":"2006","companyName":"Nippon Kayaku Co., Ltd.","relationship":"PMDA Licensee"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"12.0 hours","clearance":"1.2 mL/min/kg","fractionUnbound":"0.14%","volumeOfDistribution":"0.39 L/kg"},"publicationCount":570,"therapeuticAreas":["Other"],"atcClassification":{"source":"DrugCentral","atcCode":"H01CC02","allCodes":["H01CC02"]},"biosimilarFilings":[],"originalDeveloper":"Emd Serono Inc","recentPublications":[{"date":"2026 Mar 17","pmid":"41864162","title":"A new cetrorelix-based estrogen-free ovarian synchronization protocol for fixed-time artificial insemination in beef cattle.","journal":"Theriogenology"},{"date":"2026 May 1","pmid":"41722737","title":"Hydrogel and oleogel formulation of the decapeptide cetrorelix acetate for nasal administration.","journal":"European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences"},{"date":"2025","pmid":"41668890","title":"Targeting angiogenesis in endometriosis: a systematic review and network meta-analysis of VEGF-directed pharmacotherapies.","journal":"Frontiers in reproductive health"},{"date":"2026 Feb","pmid":"41534335","title":"Crosstalk with the cholinergic pathway may be responsible for chlorpyrifos-induced reproductive toxicity in fish.","journal":"Aquatic toxicology (Amsterdam, Netherlands)"},{"date":"2026 Dec","pmid":"41478293","title":"Oocyte cryo-preservation for fertility preservation: a comparative study of efficacy and cost-effectiveness between progestin-primed and antagonist ovarian stimulation protocol.","journal":"Human fertility (Cambridge, England)"}],"companionDiagnostics":[],"genericManufacturers":5,"_genericFilersChecked":true,"genericManufacturerList":["Gland","Livzon Grp","Qilu","Teva Pharms Inc","Xiromed"],"status":"approved","companyName":"Emd Serono Inc","companyId":"merck","modality":"Recombinant protein","firstApprovalDate":"2000","aiSummary":"","enrichmentLevel":4,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2000-08-11T00:00:00.000Z","mah":"EMD SERONO INC","brand_name_local":null,"application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"2000-08-11T00:00:00.000Z","mah":"EMD SERONO INC","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"2000-08-11T00:00:00.000Z","mah":"EMD SERONO INC","brand_name_local":null,"application_number":null},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"2000-08-11T00:00:00.000Z","mah":"EMD SERONO INC","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"2000-08-11T00:00:00.000Z","mah":"EMD SERONO INC","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"2000-08-11T00:00:00.000Z","mah":"EMD SERONO INC","brand_name_local":null,"application_number":null},{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":"2006-04-20T00:00:00.000Z","mah":"NIPPON KAYAKU CO., LTD.","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2013-01-29T00:00:00.000Z","mah":"EMD SERONO INC","brand_name_local":null,"application_number":"NDA021197"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-04-16T00:00:00.000Z","mah":"QILU","brand_name_local":null,"application_number":"ANDA217776"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-04-24T00:00:00.000Z","mah":"LIVZON GRP","brand_name_local":null,"application_number":"ANDA214540"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-04-25T00:00:00.000Z","mah":"GLAND","brand_name_local":null,"application_number":"ANDA218150"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-11-06T00:00:00.000Z","mah":"TEVA PHARMS INC","brand_name_local":null,"application_number":"ANDA215737"},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":2,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:21:02.494848+00:00","fieldsConflicting":6,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}